| Bid | 9.15 |
| Market Cap | 507.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.72 |
| PE Ratio (ttm) | -2.52 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.1 |
| Volume | 687,944 |
| Avg. Volume (20D) | 1,262,777 |
| Open | 9.69 |
| Previous Close | 9.41 |
| Day's Range | 9.24 - 10.11 |
| 52-Week Range | 1.42 - 15.10 |
| Beta | undefined |
About EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers B...
Analyst Forecast
According to 3 analyst ratings, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 60.09% from the latest price.
Next Earnings Release
Analysts project revenue of $270.50M, reflecting a -2.21% YoY shrinking and earnings per share of -0.08, making a -89.61% decrease YoY.
2 months ago · seekingalpha.com
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa MagicEmergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence po...
